Black box warnings could limit the sales of their newly approved therapeutics.
Lilly will soon discover whether its purchase of Dermira was wise.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.